VitriVax Inc.
The University of Colorado Connection
VitriVax is a biotechnology company working to eliminate barriers to global vaccination, and has developed a novel stabilization and delivery platform for vaccines and therapeutics based on research in the laboratories of Bob Garcea (CU Boulder Molecular, Cellular & Developmental Biology) and Ted W. Randolph at CU Boulder (CU Boulder Chemical and Biological Engineering).
Funding Status and Investment Opportunities
- Industry Applications: Biotech, Manufacturing, Therapeutics, Vaccines
- Funding Stage: Series B Round or beyond
- Contact for Investment Inquiries: Rom Colindres, CEO, rcolindres@vitrivaxbio.com
In the News
- VitriVax awarded $3.6M grant for Polio vaccine development (2024)
- VitriVax, a CU Boulder spinout, receives $5M grant from Gates Foundation (2023)
- VitriVax wins $29M Department of Defense contract for vaccine research (2023)
- New Buff Venture Fund makes landmark investments in CU Boulder startups (2023)
- Why developing a successful COVID-19 vaccine is only half the battle (2020)
- CU Boulder brings together top spinoffs from Colorado research institutions for Destination Startup (2019)
- State accelerator program fosters CU Boulder spin-off companies (2017)
Venture Partners Programs
- Buff Gold Venture Fund (2023)
- Destination Startup (2019)
- Intellectual Property Management (2006)
Technology Development Funding
Gates Foundation
This page was last updated on April 14, 2025. Please email vpnews@colorado.edu for corrections or updates
Media Inquiries
For marketing and communication inquiries, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.